This prospective cohort study reports that transfusion of cytomegalovirus-seronegative and leukoreduced blood products effectively prevents transmission of cytomegalovirus to very low-birth-weight infants.
This review provides an overview of measles, including information on virus basics, clinical picture and diagnosis, complications, vaccine efficacy, and vaccine complications.
This simulation study using a mathematical model of pertussis transmission assesses whether a priming dose of whole-cell pertussis vaccine is cost-effective at reducing pertussis infection in infants.
Fritz and coauthors conclude that methicillin-resistant Staphylococcus aureus (MRSA) strains concordant with infecting and colonizing strains are present on commonly handled household surfaces, a factor that likely perpetuates MRSA transmission and recurrent disease. See editorial by Milstone.
This cross-sectional study uses survey data to describe differences between virologically suppressed and virologically detectable HIV-infected young men who have sex with men and to identify correlates of condomless anal intercourse.
This serial cross-sectional survey determined that no structural changes, as measured in this study, were observed to be associated with a statistically significant reduction in risk behaviors.
This Viewpoint discusses what pediatric health care professionals should consider when treating children presenting with signs and symptoms similar to Ebola virus disease.
Papania and coauthors review the evidence for sustained elimination of endemic measles, rubella, and congenital rubella syndrome from the United States through 2011. See the editorial by Grabowsky.
This cohort study evaluates the trend of antibiotic use in very low-birth-weight infants across Canada and the association between antibiotic use rates and mortality and morbidity among neonates without culture-proven sepsis or necrotizing enterocolitis.
This study evaluates the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine’s effect over time among adolescents 11 to 18 years old and accounts for the transition from whole-cell to acellular pertussis vaccines for the childhood primary series.